Sustained Release Excipients

Sustained Release Excipients

Global Sustained Release Excipients Market to Reach US$2.4 Billion by 2030

The global market for Sustained Release Excipients estimated at US$1.6 Billion in the year 2023, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2023-2030. Polymers, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Sugars segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$433.7 Million While China is Forecast to Grow at 5.5% CAGR

The Sustained Release Excipients market in the U.S. is estimated at US$433.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$370.1 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Sustained Release Excipients Market - Key Trends and Drivers Summarized

How Are Sustained Release Excipients Enhancing Drug Delivery?

Sustained release excipients are critical components in pharmaceutical formulations designed to control the release of active ingredients over an extended period. These excipients help maintain consistent drug levels in the bloodstream, improving therapeutic effectiveness while reducing side effects and dosing frequency. Commonly used in oral tablets, capsules, injectables, and transdermal patches, sustained release excipients support various therapeutic areas, including pain management, cardiovascular diseases, and mental health treatments. As pharmaceutical companies focus on improving patient adherence and drug efficacy, sustained release formulations have gained prominence, making excipients vital in drug development.

What Are the Key Segments in the Sustained Release Excipients Market?

Key types include polymers, lipids, and carbohydrates, with polymers holding the largest market share due to their versatility, safety, and effectiveness in controlling drug release. Applications cover pain management, cardiovascular treatment, diabetes management, and CNS disorders, with pain management representing a significant segment driven by the need for consistent drug delivery to alleviate chronic pain. Formulations include tablets, capsules, injectables, and transdermal patches, with tablets leading the market due to their widespread use, cost-effectiveness, and patient acceptance.

How Are Sustained Release Excipients Integrated Across Drug Development?

In pain management, sustained release excipients help maintain steady analgesic levels, reducing dosing frequency and improving patient compliance. In cardiovascular treatments, excipients support consistent blood pressure and cholesterol control, reducing the risk of adverse events associated with peak concentrations. For diabetes management, sustained release formulations aid in stabilizing blood glucose levels, providing better glycemic control. Additionally, in mental health treatments, excipients ensure stable drug release, improving outcomes in depression, anxiety, and bipolar disorder management by maintaining consistent therapeutic levels.

What Factors Are Driving the Growth in the Sustained Release Excipients Market?

The growth in the Sustained Release Excipients market is driven by several factors, including increasing demand for controlled-release drug formulations, advancements in excipient technology, and a focus on improving patient adherence. Innovations like multifunctional excipients, better bioavailability, and enhanced safety profiles have supported broader adoption across therapeutic areas. The focus on reducing dosing frequency, managing side effects, and achieving optimal therapeutic outcomes has further fueled demand, as sustained release excipients play a crucial role in achieving these goals. Additionally, growing investments in drug development, expanding chronic disease management, and regulatory support for sustained release drugs have contributed to market growth, encouraging the use of excipients across pharmaceutical formulations.

 

SCOPE OF STUDY:

The report analyzes the Sustained Release Excipients market in terms of US$ Thousand by the following Product Segment, and Geographic Regions/Countries:

Segments:
Product Segment (Polymers, Sugars, Alcohol, Gelatin, Other Product Segments)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

• Alkermes plc
• Allergan plc
• Aradigm Corporation
• AstraZeneca
• Capsugel
• Coating Place, Inc.
• Corium International, Inc.
• Depomed, Inc.
• GlaxoSmithKline plc
• Janssen Pharmaceuticals, Inc.
• Mayne Pharma Group Limited
• Mylan N.V.
• Novartis AG
• Orbis Biosciences, Inc.
• Pfizer, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals International, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.